tag:blogger.com,1999:blog-82676772089886292122024-11-01T09:28:58.156+00:00FineNews and views from the pharmaceutical fine chemical and custom manufacturing sectorUnknownnoreply@blogger.comBlogger1763125tag:blogger.com,1999:blog-8267677208988629212.post-78511231169728214822013-03-06T20:40:00.003+00:002013-03-06T20:40:32.143+00:00Ashland expands R&D centreAshland plans to expand its formulation development and GMP contract manufacturing services for solid dispersions and oral solid dosages at its pharmaceutical R&D centre in Wilmington, DE. The expansion, which aims to support early-stage clinical trials, will include spray drying and extrusion processes previously located in Columbia, MD. Ashland said it wool relocate approximately 20 positions Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-45452318667792892142013-03-06T20:40:00.000+00:002013-03-06T20:40:02.898+00:00Strong sales at SiegfriedSiegfried has reported a 12% rise in sales to CHF367.8m for the 2012 financial year. During 2012 Siegfried opened a high potency drug production suite in Zofingen, Switzerland, made progress with plans to modernise its production facility. The company plans to start construction of a production plant in Nantong, China, during 2013.
SiegfriedUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-49013803905613615042013-03-06T20:39:00.001+00:002013-03-06T20:39:31.598+00:00DSM Pharmaceutical Products has signed a three-year master supply agreement to produce sterile products at its Greenville, NC, site for EisaiChemanagerUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-11049237780819885382013-03-06T20:38:00.003+00:002013-03-06T20:38:28.289+00:00SAFC is adding large-scale production of bulk dry power media and reagents at its manufacturing plant in Irvine, ScotlandOutsourcing PharmaUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-61513918589565759242013-03-06T20:38:00.001+00:002013-03-06T20:38:05.858+00:00Ajinomoto has entered the biopharmaceutical development and contract manufacturing arena by acquiring Althea Technologies for $175mWall Street JournalUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-53291889558992300202013-03-04T21:05:00.002+00:002013-03-04T21:05:16.780+00:00Revenues fall at CodexisCodexis reported a 29% fall in revenues in 2012 to $88.3m, which it attributed primarily to the termination of its research agreement with Shell. Additionally, product revenues fell 27% to $35.9m primarily due to the timing of orders from innovator pharmaceutical customers. Codexis said it expects to generate royalty revenues and receive a milestone payment in 2013 from its support of the Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-81129546710395629602013-03-04T21:04:00.004+00:002013-03-04T21:04:44.092+00:00The US FDA has issues a warning letter Jubilant HollisterStier for violation of cGMP practices at its Kirkland, Quebec, Canada, facilityHindu Business LineUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-75485374466011189062013-03-04T21:04:00.002+00:002013-03-04T21:04:20.641+00:00Genmab finally sells facilityGenmab will sell its non-plasma-derived antibody manufacturing facility, in Brooklyn Park, MN, to Baxter Healthcare for $10m. Baxter will also offer employment to Genmab's employees at the site. Genmab has been trying to sell the facility for a number of years and had written off the value to zero.
GenmabUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-59546879533662262652013-03-04T21:03:00.005+00:002013-03-04T21:03:53.012+00:00Construction has not yet started on the construction of Lonza's Ketlaphela joint venture facility in South Africa due to issues with funding and competitivenessIn-pharma TechnologistUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-28639177591677545552013-03-04T21:03:00.003+00:002013-03-04T21:03:28.779+00:00Viropro will manufacture six monoclonal antibody products being developed by OncobiologicsPharmaceutical Business ReviewUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-88069659662441493402013-03-04T21:03:00.001+00:002013-03-04T21:03:02.120+00:00Evonik's owners have revived plans to list the company in an IPOReutersUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-26140728921295292712013-02-21T20:29:00.001+00:002013-02-21T20:29:21.546+00:00BASF and Bend Research will jointly evaluate and develop novel excipients to enhance the solubility and bioavailability of poorly soluble drugsBASFUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-36095671338465889052013-02-20T20:43:00.004+00:002013-02-20T20:43:35.147+00:00Lonza will generate induced pluripotent stem cells for research purposes for the US National Institutes of Health Center for Regenerative Medicine at its Walkersville, MD, facilityLonzaUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-54254785378716941132013-02-20T20:43:00.002+00:002013-02-20T20:43:11.879+00:00DSM pharma sales rise in 2012DSM reported full year 2012 sales rising 9% to €726m, which the company attributed to increased volumes at DSM Pharmaceutical Products. DSM expects the business conditions for the pharma sector to remain challenging in 2013 but is confident of being able to deliver substantially better results during the year.
DSMUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-65211949174198807162013-02-19T20:30:00.003+00:002013-02-19T20:30:52.726+00:00Strem will distribute Codexis' Codex Screening Kits for transaminase and ketoreductase enzyme platformsStremUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-75908742130060205262013-02-19T20:30:00.001+00:002013-02-19T20:30:29.245+00:00DSM Pharmaceutical Products and Chemtrix will provide continuous flow chemistry equipment, development and manufacturing services to the pharmaceutical industryGENUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-34966465505025970682013-02-18T20:17:00.004+00:002013-02-18T20:17:46.942+00:00Recipharm is manufacturing clinical trial material for PledPharma's PledOxContract PharmaUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-75255253725757157202013-02-18T20:17:00.002+00:002013-02-18T20:17:20.445+00:00Saltigo will provide process development and commercially manufacture Relypsa's hyperkalemia treatmentSaltigoUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-18018469729199001652013-02-14T20:44:00.004+00:002013-02-14T20:44:54.521+00:00Cambrex will manufacture hydroxypropyl methylcellulose acetate succinate for Dow Chemical for use in drug solubility enhancementCambrexUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-72708125167936001972013-02-14T20:44:00.002+00:002013-02-14T20:44:33.322+00:00AMRI will use enzymes developed by Codexis to develop cheaper routes to manufacture APIs and intermediatesPharmaceutical Business ReviewUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-89704275741862017812013-02-14T20:44:00.000+00:002013-02-14T20:44:07.463+00:00Mixed manufacturing results at AMRIAMRI reported development/small scale manufacturing revenues for 2012 were $35.7m, essentially flat with 2011. However, revenues for the large scale m rose 22% to $116.4m. Michael Nolan, AMRI's Vice President, Chief Financial Officer and Treasurer, said the company expects development and small scale revenues to rise up to 7% in 2013 and large scale revenue to rise up to 14%.
Seeking AlphaUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-60076740875069379462013-02-14T20:43:00.000+00:002013-02-14T20:43:07.141+00:00Ash Stevens' expansion almost completeAsh Stevens has completed construction on the expansion of its cGMP manufacturing facility in Riverview, MI, and expects to complete commissioning and validation by April. The new large-scale reactor bay houses 2000, 3000 and 4000L glass-lined vessels and an new isolation bay is equipped with a 1.5m2 fixed filter dryer.
Pharmaceutical OutsourcingUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-47733802423112442942013-02-12T21:02:00.006+00:002013-02-12T21:02:52.925+00:00Albemarle has started a $30m capacity expansion at its Tyrone, PA, custom manufacturing facilityAlbemarleUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-86541118046548307342013-02-12T21:02:00.004+00:002013-02-12T21:02:28.053+00:00Angel Bio enters administrationTrading in shares of Angel Biotechnology has been suspended as the company entered administration. The company has appointed KPMG as administrators after talks to enter into a strategic relationship with another party fell through.
BBCUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-8267677208988629212.post-88614439108555851272013-02-12T21:02:00.001+00:002013-02-12T21:02:01.525+00:00Sigma Aldrich reported sales growth of 17% to $855m for its SAFC businessSeeking AlphaUnknownnoreply@blogger.com0